JPMorgan Chase & Co. Has Lowered Expectations for ICON Public (NASDAQ:ICLR) Stock Price

ICON Public (NASDAQ:ICLR) had its price objective dropped by investment analysts at JPMorgan Chase & Co. from $280.00 to $265.00 in a report issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 37.11% from the stock’s previous close.

ICLR has been the topic of a number of other research reports. Truist Financial restated a “buy” rating and issued a $284.00 target price (down from $295.00) on shares of ICON Public in a research note on Wednesday, December 18th. Barclays reduced their price objective on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a research report on Wednesday, January 15th. Evercore ISI reduced their price target on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Finally, Citigroup dropped their price objective on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $285.75.

ICON Public Stock Performance

Shares of ICON Public stock opened at $193.27 on Monday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72. The firm’s 50-day simple moving average is $208.53 and its 200-day simple moving average is $256.54. The firm has a market cap of $15.94 billion, a PE ratio of 21.55, a price-to-earnings-growth ratio of 1.79 and a beta of 1.19.

Institutional Trading of ICON Public

Several hedge funds have recently added to or reduced their stakes in ICLR. Sierra Ocean LLC acquired a new position in shares of ICON Public during the fourth quarter worth about $29,000. Park Place Capital Corp grew its stake in shares of ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after acquiring an additional 166 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 169 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of ICON Public by 23.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its position in ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 151 shares in the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.